These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7562403)

  • 21. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
    El-Kamel AH; Abdel-Aziz AA; Fatani AJ; El-Subbagh HI
    Int J Pharm; 2008 Jun; 358(1-2):248-55. PubMed ID: 18502065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on the enzyme dependant colon targeting prodrug--dexamethasone succinate dextran and its tablets].
    Pang YN; Zhang ZR; Pang QJ; Li TL
    Yao Xue Xue Bao; 2001 Aug; 36(8):625-30. PubMed ID: 12579944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macromolecular prodrug of 4-aminosalicylic acid for targeted delivery to inflamed colon.
    Vadnerkar G; Dhaneshwar S
    Curr Drug Discov Technol; 2013 Mar; 10(1):16-24. PubMed ID: 22725691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.
    Kolkman JJ; Möllmann HW; Möllmann AC; Penã AS; Greinwald R; Tauschel HD; Hochhaus G
    Drugs Today (Barc); 2004 Jul; 40(7):589-601. PubMed ID: 15510233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
    Li F; Wu G; Zheng H; Wang L; Zhao Z
    Eur J Med Chem; 2016 Jan; 108():486-494. PubMed ID: 26717200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivery of glucocorticoid conjugate in rat gastrointestinal tract and its treatment for ulcerative colitis.
    Zhou SY; Mei QB; Liu L; Guo X; Qiu BS; Zhao DH; Cho CH
    Acta Pharmacol Sin; 2001 Aug; 22(8):761-4. PubMed ID: 11749853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery.
    Kim D; Kim W; Jeong S; Kim D; Yoo JW; Jung Y
    Drug Deliv Transl Res; 2019 Feb; 9(1):334-343. PubMed ID: 30426357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.
    Xian S; Zhu J; Wang Y; Song H; Wang H
    Drug Deliv; 2023 Dec; 30(1):2183821. PubMed ID: 36861451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
    Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
    Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical anticolitic efficacy and selectivity of the glucocorticoid budesonide in a new model of acetic acid-induced acute colitis in the rat.
    Fabia R; Ar'Rajab A; Willén R; Brattsand R; Erlansson M; Svensjö E
    Aliment Pharmacol Ther; 1994 Aug; 8(4):433-41. PubMed ID: 7986968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Locally acting glucocorticoids in chronic intestinal inflammation].
    Lamers CB; van der Sluys Veer A; Wagtmans MJ; van Hogezand RA
    Ned Tijdschr Geneeskd; 1994 Dec; 138(51):2533-5. PubMed ID: 7830800
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral budesonide therapy for ulcerative colitis: a topical tale.
    Feagan BG
    Gastroenterology; 1996 Jun; 110(6):2000-2. PubMed ID: 8964430
    [No Abstract]   [Full Text] [Related]  

  • 34. Budesonide-hydroxypropyl-β-cyclodextrin inclusion complex in binary poloxamer 407/403 system for ulcerative colitis treatment: A physico-chemical study from micelles to hydrogels.
    Santos Akkari AC; Ramos Campos EV; Keppler AF; Fraceto LF; de Paula E; Tófoli GR; de Araujo DR
    Colloids Surf B Biointerfaces; 2016 Feb; 138():138-47. PubMed ID: 26674842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats.
    Chopade SS; Dhaneshwar SS
    World J Gastroenterol; 2018 Mar; 24(10):1093-1106. PubMed ID: 29563754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation.
    Sarkate A; Dhaneshwar SS
    World J Gastroenterol; 2017 Feb; 23(7):1147-1162. PubMed ID: 28275295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical and oral anti-inflammatory activity of budesonide compared with oral prednisolone in an animal model using allergen-induced gut mucosal exudation of plasma as a marker.
    Gustafsson B; Miller-Larsson A; Persson CG
    Scand J Gastroenterol; 2001 Oct; 36(10):1062-6. PubMed ID: 11589379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
    Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
    J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciclesonide and budesonide suspensions for nebulization delivery: An in vivo inhalation biopharmaceutics investigation.
    Fu TT; Zhao Y; Yang FF; Wen H; Liu CY; Liao YH
    Int J Pharm; 2018 Oct; 549(1-2):21-30. PubMed ID: 30048776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.